Home/ Stocks/ ATNM

Actinium Pharmaceuticals, Inc

ATNM XASE

$1.07 -0.07 (-6.14%) ▼ 15-min delayed

Open

$1.12

High

$1.15

Low

$1.07

Volume

197.2K

Market Cap

$35.56M

About Actinium Pharmaceuticals, Inc

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 31 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$90.0K	$-5,131,000	$-0.16
Q2 2025	$0	$-6,878,000	$-0.22
Q1 2025	$0	$-15,938,000	$-0.51
FY 2024	$0	$-38,243,000	$-1.27

Related Market News

No specific coverage for ATNM yet. Check out our latest market news or earnings calendar.

Get ATNM Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Actinium Pharmaceuticals, Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.